Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
N.E.E. 1/35 21 vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Prevention of pregnancy (FDA-approved)
Prevention of pregnancy
One tablet orally once daily for 21 days, followed by 7 days off.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Norethindrone: terminal half-life 7-8 hours; Ethinyl estradiol: terminal half-life 12-14 hours (with enterohepatic recycling). Clinically, steady state achieved after 5-7 days.
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Ethinyl estradiol: primarily hepatic via CYP3A4, undergoes conjugation (glucuronidation and sulfation). Norethindrone: hepatic reduction and conjugation, also metabolized by CYP3A4. Both undergo enterohepatic recirculation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Norethindrone (NET) and ethinyl estradiol (EE) are excreted primarily in urine (~50-60% as metabolites) and feces (~30-40% as metabolites); less than 1% excreted unchanged.
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Norethindrone: ~97% bound (albumin, SHBG); Ethinyl estradiol: ~98% bound (albumin).
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
Norethindrone: Vd 4-5 L/kg; Ethinyl estradiol: Vd 3-4 L/kg; indicates extensive tissue distribution.
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: Norethindrone ~64%; Ethinyl estradiol ~45% (first-pass metabolism).
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
No dose adjustment required. Use with caution in severe impairment.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment).
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not indicated in prepubertal children; use only after menarche per adult dosing.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
Not indicated for contraception postmenopausal; use lowest effective dose for hormone therapy if applicable.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and with heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Cigarette smoking significantly increases cardiovascular risk (see boxed warning),Elevated blood pressure,Hepatic neoplasia (benign and malignant) reported with long-term use,Gallbladder disease,Carbohydrate and lipid metabolic effects (monitor in prediabetic/diabetic patients),Headache (including migraine), discontinue if new or worsening pattern,Bleeding irregularities (breakthrough bleeding, amenorrhea),Chloasma (may persist after discontinuation),Retinal thrombosis (discontinue if unexplained vision loss)
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Thrombophlebitis, venous thromboembolism (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (current or history),Estrogen-dependent neoplasia (current or history),Hepatic adenoma or carcinoma (current or history),Active liver disease or impaired hepatic function (including jaundice with prior pill use),Major surgery with prolonged immobilization,Hypersensitivity to any component of the product,Age >35 years and smoking
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Avoid grapefruit and grapefruit juice during treatment due to potential increase in estrogen exposure and risk of adverse effects. No other significant food interactions reported.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
N. E. E. 1/35 21 (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects based on population data, but should not be used once pregnancy is confirmed. Second and third trimesters: Known risks include feminization of male fetus, cardiovascular and skeletal abnormalities, and potential for long-term effects on the child. Immediate discontinuation if pregnancy occurs.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Contraindicated in breastfeeding. Estrogen and progestins pass into breast milk; may reduce milk quantity and quality. Estrogen can suppress lactation. M/P ratio for norethindrone is approximately 0.5–1.0; for ethinyl estradiol, M/P ratio is about 0.2. Use postpartum only after breastfeeding is fully established and only if no alternative. Generally avoid.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
No dosing adjustments applicable as drug is contraindicated in pregnancy. If inadvertently used, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not relevant due to contraindication.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
N. E. E. 1/35 21 is a monophasic combined oral contraceptive containing 1 mg norethindrone and 35 mcg ethinyl estradiol. It can be used for cycle control and dysmenorrhea. Missed pill management: if one pill is missed, take it as soon as remembered; if two or more are missed, use backup contraception for 7 days. Consider potential drug interactions with rifampin, certain anticonvulsants, and St. John's Wort which may reduce efficacy.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take one tablet daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, take it as soon as you remember. If more than one pill is missed, use backup contraception.,This medication does not protect against sexually transmitted infections.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots such as leg pain/swelling, chest pain, or sudden shortness of breath.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about N.E.E. 1/35 21 vs ALYACEN 1/35, answered by our medical review team.
N.E.E. 1/35 21 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between N.E.E. 1/35 21 and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of N.E.E. 1/35 21 is: One tablet orally once daily for 21 days, followed by 7 days off.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between N.E.E. 1/35 21 and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. N.E.E. 1/35 21 is classified as Category C. N.E.E. 1/35 21 (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects based on population data, but should not. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.